Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2296 - TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer – final results from the randomized phase II trial of the AIO


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy

Tumour Site

Colon and Rectal Cancer


Thomas Ettrich


Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281


T.J. Ettrich1, A.W. Berger1, T. Decker2, R.D. Hofheinz3, V. Heinemann4, T. Hoffmann5, H.F. Hebart6, T. Herrmann7, C. Hannig8, P. Büchner-Steudel9, H. Bartholomäus1, M. Güthle1, L. Perkhofer1, T. Seufferlein1

Author affiliations

  • 1 Department Of Internal Medicine I  , Ulm University, 89081 - Ulm/DE
  • 2 Private Practice, Onkologie Ravensburg, 88212 - Ravensburg/DE
  • 3 Interdisciplinary Tumor Center, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 4  department Of Medical Oncology And Comprehensive Cancer Center, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 5 Internal Medicine Ii, Klinikum Weimar, Weimar/DE
  • 6 Department Of Internal Medicine, Stauferklinikum Schwäbisch Gmünd, 73557 - Mutlangen/DE
  • 7 Medizinische Klinik, Westküstenklinikum Heide, 25746 - Heide/DE
  • 8 Private Practice, Schwerpunktpraxis Haematologie / Onkologie, 46236 - Bottrop/DE
  • 9 Internal Medicine I, Martin-Luther-University Halle-Wittenberg, 06120 - Halle/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2296


Anti-VEGF agents in combination with chemotherapy improve PFS of patients with mCRC in the 1st- and 2nd-line-setting. During anti-VEGF treatment tumour angiogenesis is driven by other factors but VEGF. Nintedanib is a triple angiokinase inhibitor of human VEGFR-1-3, FGFR-1/-3 and PDGFR-α/-β thereby additionally targets angiogenic escape mechanisms upon resistance to anti-VEGF treatment. The TRICC-C trial evaluates the combination of mFOLFOX6 plus Nintedanib. Final results of the randomized phase II trial are presented.


Patients with mCRC having received one line of non-oxaliplatin containing palliative chemotherapy, with an ECOG-PS of 0 or 1 were randomized 1:1 in a double-blind design to receive: mFOLFOX6 plus Nintedanib (2 x 200 mg p.o./d, d1-d14) or placebo, respectively, repeated every 14 days. Primary endpoint was PFS. Secondary endpoints were ORR, OS and safety. Patients who received at least one dose of trial medication were included in the efficacy and safety analyses.


From 12/2012 to 5/2016 53 patients (scheduled n = 180) were randomized. The trial was terminated prematurely due to slow accrual. Compared to mFOLFOX6 plus placebo (F+P), the combination of mFOLFOX6 plus Nintedanib (F+N) improved mPFS (F+P: 4.6 vs F+N: 8.1 mo.; HR 0.65; 95% CI 0.32-1.30; p = 0.2156), mOS (F+P: 9.9 vs. F+N: 17.1 mo.; HR 1.03, 95% CI 0.48-2.23; p = 0.9387) and DCR (F+P: 50 vs. F+N: 66,7%; p = 0.2709). ORR was comparable in both arms (F+N: 3.8 vs. F+P: 3.7%). Toxicity was low to moderate without major differences between both arms except G 3/4 neutropenia (F+N: 19%, F+P: 12%) and GI disorders (F+N: 23%, F+P: 15%).


Final results suggest a PFS, OS and DCR benefit for mFOLFOX6 + Nintedanib vs. mFOLFOX6 + placebo in the 2nd-line therapy of mCRC. Due to the premature termination of the trial there was no statistical significance demonstrable. Showing no clinically significant PFS-benefit in the 1st-line situation (mFOLFOX6 plus Nintedanib/Bevacizumab, Ann Oncol. 2015) or the last line as single agent, respectively (ESMO 2016) the TRICC-C results suggests that Nintedanib could be an interesting therapeutic option for the 2nd-line situation in combination with mFOLFOX6.

Clinical trial identification


Legal entity responsible for the study

Martin-Luther-Universität Halle-Wittenberg, Germany.


Boeringer Ingelheim.

Editorial Acknowledgement


T.J. Ettrich: Research grants: Baxalta/Shire; Consulting fees or other remuneration: Merck-Serono, Sanofi, Sirtex, Medical, Novartis, Bayer, Bristol-Myers Squibb, Pfizer. A.W. Berger: Consulting fees: Sanofi. R.D. Hofheinz: Consulting or advisory role: Boehringer Ingelheim. T. Seufferlein: Research Funding: Celgene, Sanofi Consulting or Advisory role: Celgene, Lilly Pharma, Boehringer Ingelheim, Merck Serono, Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.